Previous Article | Next Article 
Infection and Immunity, May 2001, p. 2957-2963, Vol. 69, No. 5
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.5.2957-2963.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Pathogenic Yeasts Cryptococcus
neoformans and Candida albicans Produce
Immunomodulatory Prostaglandins
Mairi C.
Noverr,1,2
Susan M.
Phare,1
Galen B.
Toews,1
Michael J.
Coffey,1 and
Gary B.
Huffnagle1,2,*
Division of Pulmonary and Critical Care
Medicine, Department of Internal Medicine,1 and
Department of Microbiology and
Immunology,2 University of Michigan Medical
School, Ann Arbor, Michigan 48109-0642
Received 16 November 2000/Returned for modification 13 December
2000/Accepted 30 January 2001
 |
ABSTRACT |
Enhanced prostaglandin production during fungal infection could be
an important factor in promoting fungal colonization and chronic
infection. Host cells are one source of prostaglandins; however,
another potential source of prostaglandins is the fungal pathogen
itself. Our objective was to determine if the pathogenic yeasts
Cryptococcus neoformans and Candida albicans
produce prostaglandins and, if so, to begin to define the role of these
bioactive lipids in yeast biology and disease pathogenesis. C. neoformans and C. albicans both secreted
prostaglandins de novo or via conversion of exogenous arachidonic acid.
Treatment with cyclooxygenase inhibitors dramatically reduced the
viability of the yeast and the production of prostaglandins, suggesting
that an essential cyclooxygenase like enzyme may be responsible for
fungal prostaglandin production. A PGE series lipid was purified from
both C. albicans and C. neoformans and was
biologically active on both fungal and mammalian cells. Fungal
PGEx and synthetic PGE2 enhanced the
yeast-to-hypha transition in C. albicans. Furthermore, in
mammalian cells, fungal PGEx down-modulated chemokine
production, tumor necrosis factor alpha production, and splenocyte
proliferation while up-regulating interleukin 10 production. These are
all activities previously documented for mammalian PGE2.
Thus, eicosanoids are produced by pathogenic fungi, are critical for
growth of the fungi, and can modulate host immune functions. The
discovery that pathogenic fungi produce and respond to immunomodulatory
eicosanoids reveals a virulence mechanism that has potentially great
implications for understanding the mechanisms of chronic fungal
infection, immune deviation, and fungi as disease cofactors.
 |
INTRODUCTION |
Prostaglandins are potent regulators
of host immune responses. They are produced following the action of a
cyclooxygenase on dihomo-
-linolenic, arachidonic, or
eicosanopentaenoic acid (20). The activities of
prostaglandins on mammalian cells are numerous. Prostaglandins can
inhibit Th1-type immune responses, chemokine production, phagocytosis,
and lymphocyte proliferation (1, 11, 16, 18, 20, 23, 26,
27). Prostaglandins can also promote Th2-type responses
and tissue eosinophilia (4, 16, 20, 24). In the context of
anti-fungal immunity, chronic or disseminating fungal infections will
result if the Th1-Th2 balance of cellular immunity is shifted away from
Th1- toward Th2-type responses (21). The role of
prostaglandins in promoting fungal virulence remains to be determined.
However, elevated prostaglandin levels have been observed in chronic
Candida albicans infections (28). Thus,
enhanced prostaglandin production during fungal infection could be an
important factor in promoting fungal colonization and chronic infection.
Host cells are one source of prostaglandins during fungal infection;
however, another potential source of prostaglandins is the fungal
pathogen itself. There have been reports in the literature of
eicosanoid production by slime molds and soil fungi (12). Our objective was to determine if the pathogenic yeasts
Cryptococcus neoformans and C. albicans produce
prostaglandins and, if so, to begin to define the role of these
bioactive lipids in yeast biology and disease pathogenesis.
 |
MATERIALS AND METHODS |
Determination of prostaglandin concentration by ELISA.
C. neoformans strains 24067E and H99 and C. albicans strain CHN1 (a clinical isolate) were grown to stationary
phase (72 h) at 25°C in Sabouraud dextrose broth (SDB) (1%
neopeptone, 2% dextrose; Difco, Detroit, Mich.) or asparagine broth
(AspB) (0.1% asparagine, 0.05% MgSO4 · 7H2O, 0.3% glucose, 0.0001% thiamine; Sigma Chemical Co.,
St. Louis, Mo.) with shaking. The culture supernatants were analyzed
for prostaglandin production using a monoclonal PGE2 enzyme-linked immunosorbant assay (ELISA) (Cayman Chemicals, Ann Arbor,
Mich.) or a prostaglandin screening enzyme immunoassay kit (the
specificity is described in Results; Cayman Chemicals).
HPLC analysis of arachidonic acid metabolites
secreted by C. neoformans.
Strain 24067E was grown to
stationary phase (72 h) in SDB, and 5 × 106 CFU was
incubated with 0.5 µCi of [3H]arachidonic acid
(DuPont-NEN, Boston, Mass.) in 1 ml of SDB at 37°C for 30 min. Lipid
residues were extracted using Sep-Pac C18 cartridges
(Waters Associates, Milford, Mass.), evaporated under nitrogen, and
stored at
70°C. The dehydrated samples were then dissolved in 1 ml
of acetonitrile-water-trifluoroacetic acid and analyzed by
reverse-phase high performance liquid chromatography (HPLC) on a 5-µm
Bondapak C18 column (30 by 0.4 cm; Waters Associates) using
a mobile phase of acetonitrile-water-trifluoroacetic acid at a flow
rate of 2 ml/min. Arachidonic acid metabolites were eluted during a
series of linear gradient increases of acetonitrile from initial
conditions of 50:50:0.1 (vol/vol/vol) to 73:27:0.1 (vol/vol/vol) at 7 min, then to 85:15:0.1 (vol/vol/vol) at 9 min, and finally to 100:0:0.1
(vol/vol/vol) at 15 min. The eluate was continuously monitored for UV
absorbance, and peaks were identified on the basis of their coelution
with authentic standards. Radioactivity was quantitated by liquid
scintillation counting.
Cyclooxygenase inhibitor assay.
C. neoformans
strain H99 and C. albicans strain CHN1 were grown in SDB for
24 h at 25°C. Indomethacin (Sigma Chemical Co.) was dissolved in
dimethyl sulfoxide (DMSO) to a stock concentration of 100 mM.
Indomethacin was added to the yeast cultures to give a final
concentration of 1.0 mM, while the control cultures contained DMSO
alone. The cultures were incubated with shaking for an additional 24 h at 25°C.
Purification of fungal PGEx.
C.
neoformans strain H99 and C. albicans strain CHN1 were
grown to stationary phase (72 h) in SDB at 25°C. The culture
supernatants were loaded onto a PGE2 affinity column
(Cayman Chemicals), washed, and eluted according to the manufacturer's
instructions. The eluates were dried and resuspended in buffer, and the
PGEx concentrations were determined.
C. albicans germ tube assay.
A standard germ
tube assay was performed in which C. albicans was
resuspended in 100% fetal calf serum (FCS) (Sigma Chemical Co.),
purified PGEx was added to the cell suspension to give
final concentrations of 0.33 nM PGE2 and 66% FCS, and the
cells were incubated at 37°C for 2 h. Samples were removed in
duplicate, and 400 cells were counted under 200× power using
phase-contrast microscopy. The mean numbers of budding yeast forms and
germ tube forms were determined.
Mitogen-induced lymphocyte proliferation and cytokine
production.
Splenocytes were harvested from CBA/J mice and plated
in 96-well tissue culture plates at 5 × 105/well with
a 0.65 nM (250 pg/ml) final concentration of purified fungal
PGEx or commercially available PGE2 (Cayman
Chemicals) and 5 µg of conconavalin A (ConA) (Sigma Chemical Co.)/ml.
The cultures were incubated for 48 h at 37°C and pulsed with 5 µCi of [3H]thymidine/ml for an additional 16 h at
37°C. The cells were harvested on paper filters, and the amount of
[3H]thymidine incorporated was measured by liquid
scintillation counting. For cytokine production, cell supernatants from
ConA-stimulated splenocyte cultures were harvested after 24 h of
incubation at 37°C, and cytokines were measured by ELISA for
interleukin 10 (IL-10) and tumor necrosis factor alpha (TNF-
; BD
PharMingen, San Diego, Calif.).
Cytokine production by human epithelial cells.
A549 human
epithelial cells were trypsinized and plated on 12-well tissue culture
plates at 105/well. The cells were grown to confluency (24 h) and treated with a 0.65 nM (250 pg/ml) final concentration of
purified fungal PGEx or commercially available
PGE2 (Cayman Chemicals). For IL-6 induction, TNF-
(10 ng/ml) was added to the cultures. The culture supernatants were
harvested after 24 h, and the cytokines were analyzed by ELISA for
IL-8 and IL-6 (BD PharMingen).
Statistical analysis.
Student's t test (two
tailed; unequal variance) was used to analyze the significance of
differences between experimental groups. Data with a P value
of 0.05 or less were considered to be significant.
 |
RESULTS |
To determine whether C. neoformans could produce
prostaglandins, broth cultures of strain 24067E were assayed by
monoclonal anti-PGE2 ELISA. The different classes of
prostanoids (PGA, PGB, PGD, PGF, and TXB) have the same basic molecular
structure, differing only in the oxygen substitution of the
five-membered ring portion of the lipid. The PGE2 ELISA
utilized in these experiments exhibits cross-reactivity with
prostaglandins of the E class only, which includes PGE1
(19%), PGE2 (100%), and PGE3 (43%). The
PGE2 ELISA does not recognize prostanoids of the PGA, PGB,
PGD, PGF, or TXB class or isomers of PGE2. Thus, we will
refer to the prostaglandins detected as PGEx. The yeasts
were grown to stationary phase (72 h) in AspB, a defined minimal medium
of salts, glucose, thiamine, and asparagine. PGEx was
detected in C. neoformans AspB culture supernatants
(34.2 ± 8.2 pg/ml). We also detected PGEx in culture supernatants from C. neoformans grown in SDB, an undefined
nutrient-rich broth containing glucose and neopeptone (117.4 ± 29.2 pg/ml). Prostaglandin production was detected at both 25 and
37°C, with slightly higher levels of prostaglandins detected at
25°C (data not shown). Lipids were also extracted from the C. neoformans broth samples and assayed for PGEx.
Significant levels of PGEx were detected in the extracts,
confirming the lipid nature of these molecules (data not shown). These
results demonstrate that C. neoformans can produce and
secrete PGEx into its surroundings and can synthesize
PGEx without an exogenous source of arachidonic acid (AspB).
We next examined whether C. neoformans could utilize
exogenous sources of arachidonic acids to produce eicosanoids.
Cryptococci were incubated with [3H]-arachidonic acid to
generate labeled eicosanoids for HPLC analysis. The major arachidonic
acid metabolite produced by C. neoformans coeluted with an
authentic PGD2 standard. Other cryptococcal eicosanoids coeluted with authentic HHT, 5-HETE, PGF2,
TXB2, and PGE2 (Fig. 1). Interestingly, we also detected large
amounts of two other eicosanoids, U1 and U2 (Fig. 1). A similar pattern
of peaks was observed from HPLC analysis of C. albicans
culture supernatant, with the exception that C. albicans has
an additional peak that coelutes with 15-HETE (data not shown). Given
the heterogeneity of prostaglandin products detected by HPLC, a
polyclonal prostaglandin-screening ELISA was used to analyze total
prostaglandin levels. This ELISA detects PGE2,
PGD2, and TXB2 along with PGE1,
PGE3, PGF1
, PGF2
, and
PGF3
. It does not detect the PGA class,
PGB1, 15-keto PGE2, 13,14-dihydro-15-keto
PGF2
, or misopristol. For C. neoformans, we
detected higher levels of prostaglandins with the prostaglandin ELISA
(>1,500 pg/ml) than with the monoclonal PGE2 ELISA (~120
pg/ml), confirming the results of the HPLC analysis (Fig. 1). Thus,
C. neoformans can utilize exogenous sources of arachidonic
acid to produce a number of different eicosanoids.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 1.
Secretion of arachidonic acid metabolites by C. neoformans. Strain 24067E was grown to stationary phase (72 h) and
was incubated with 0.5 µCi of [3H]arachidonic acid
(3H-AA) in 1 ml of SDB at 37°C for 30 min. The
supernatant was analyzed by HPLC, and peaks were identified on the
basis of their coelution with authentic standards. Pc, prostacyclin.
|
|
To determine whether other pathogenic yeasts also produce
prostaglandins, we assayed the prostaglandin levels in broth cultures of a number of C. albicans and C. neoformans
strains. C. albicans strain CHN1 secreted significant
amounts of prostaglandins (>1,800 pg/ml), including PGEx
(~130 pg/ml, comparable to the levels produced by C. neoformans strain 24067E PGEx [~120 pg/ml]). A
number of clinical and laboratory strains of C. neoformans
(H99, 145, 184, and 602) and C. albicans (28366 and 36082)
were analyzed, and all produced significant amounts of prostaglandins
in culture, although there was strain-to-strain variation in the levels
even when they were normalized to numbers of CFU (data not shown). Similar to C. neoformans, C. albicans synthesized
prostaglandins de novo (in AspB) and in greater quantities if the
medium was supplemented with exogenous arachidonic acid (data not
shown). Altogether, these results demonstrate by three independent
assays that the pathogenic yeasts C. neoformans and C. albicans synthesize and secrete prostaglandins, including a PGE
series compound (PGEx).
We next tested the effect of cyclooxygenase inhibitors on fungal
PGEx production and fungal growth (Fig.
2). Cyclooxygenases are the enzymes that
catalyze the conversion of arachidonic acid into the prostaglandins in
mammalian cells. The cyclooxygenase inhibitor indomethacin was added to
exponentially growing cultures of C. neoformans and C. albicans and incubated with shaking for an additional 24 h.
Indomethacin inhibited C. neoformans and C. albicans PGEx production by 65 and 54%, respectively
(Fig. 2A). Strikingly, indomethacin treatment also sharply reduced the
viability of these fungi. After 24 h, 99.9% of C. neoformans and 95.7% of C. albicans cells were killed
(Fig. 2B). Similar decreases in viability were observed with the
cyclooxygenase inhibitors etodolac and piroxicam (data not shown).
Therefore, the decrease in yeast viability and PGEx
production was not due to a nonspecific toxicity of indomethacin for
the yeast cells. Thus, cyclooxygenase plays a critical role in fungal
metabolism (including PGEx production), and inhibition of
cyclooxygenase activity decreases the viability of C. neoformans and C. albicans.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 2.
Effect of cyclooxygenase inhibitors on prostaglandin
production and survival of C. neoformans and C. albicans. Cultures of C. neoformans strain H99 and
C. albicans strain CHN1 were grown for 24 h at 25°C.
Indomethacin (1.0 mM dissolved in DMSO) was added, and the cultures
were then incubated for an additional 24 h. Control cultures
contained DMSO alone. The numbers in parentheses represent percent
inhibition of PGE2 compared to control (A) and percent
killing compared to initial CFU per milliliter measured before the
addition of inhibitor (B). The results represent the averages (± standard errors) of two independent experiments. *, P < 0.05 compared to control.
|
|
To assess the activities of fungal prostaglandins on fungal biology, we
examined the effects of purified fungal PGEx on germ tube
formation in C. albicans (Fig.
3). Germ tube formation is the initial
step in the yeast-to-hypha phase transition. Using an affinity
purification system with the same monoclonal PGE2 antibody
used in the ELISA, we specifically isolated PGEx from both
C. albicans and C. neoformans and compared it to
commercially available PGE2. The addition of
affinity-purified Candida PGEx to C. albicans yeast cells enhanced germ tube formation (Fig. 3).
Affinity-purified Cryptococcus PGEx and
commercial PGE2 also enhanced germ tube formation in
C. albicans (Fig. 3). The addition of indomethacin
completely blocked germ tube formation induced by serum alone (data not
shown). However, no viable Candida yeasts were recovered
after indomethacin incubation (data not shown), confirming the results
shown in Fig. 2B indicating that cyclooxygenase activity is required
for yeast viability. Thus, both host PGE2 and fungal
PGEx can enhance yeast-to-hypha phase transition in C. albicans.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 3.
Effects of exogenous prostaglandins on C. albicans germ tube formation. C. albicans was incubated
in FCS with either buffer, commercially available PGE2, or
affinity-purified fungal PGEx. Ca, C. albicans; Cn,
C. neoformans. The results represent the averages (± standard
errors) of three independent experiments. *, P < 0.05 compared to buffer alone.
|
|
To assess the activity of fungal prostaglandins on mammalian cell
biology, we addressed whether fungal PGEx can modulate
mammalian-cell cytokine production and proliferation as has been
reported for mammalian PGE2. The four assays used were (i)
inhibition of mitogen-induced lymphocyte proliferation, (ii) inhibition
of TNF-
production, (iii) enhancement of IL-10 production, and (iv)
inhibition of chemokine production (11, 23, 26, 27). We
chose to test the biological activity of the fungal PGEx
throughout these studies at a concentration (0.65 nM) that might be
found in tissue at a site of infection (in vitro experiments typically
use between 10 and 1,000 nM). Murine splenocytes were stimulated with
mitogen (ConA) in the presence or absence of 0.65 nM commercially
available PGE2 or PGEx purified from C. albicans or C. neoformans. Fungal PGEx and
PGE2 both suppressed ConA-induced lymphocyte proliferation (Fig. 4). The human epithelial cell line
A549 constitutively produces the CXC chemokine IL-8. Fungal
PGEx and PGE2 both reduced IL-8 production from
the bronchial epithelial cell line (Fig.
5A). While the inhibition of IL-8
production was not dramatic (23 to 32%), this low dose of fungal
PGEx did produce a measurable effect. PGEx from
both C. albicans and C. neoformans also inhibited
TNF-
production and enhanced IL-10 production by mitogen-stimulated splenocytes (Fig. 6). The
PGEx preparations used in these assays did not affect
phorbol myristate acetate-ionomycin-induced proliferation of the
splenocytes or IL-6 induction by the A549 cells, thereby verifying that
the preparations did not contain a toxic contaminant (Fig. 4 to 6).
These experiments demonstrate that even at low levels fungal
PGEx is biologically active on mammalian cells and has
activity similar to that reported for mammalian PGE2
(23, 26).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 4.
Effect of fungal PGE2 on mitogen-induced
lymphocyte proliferation in murine splenocytes. Ca, C. albicans;
Cn, C. neoformans. Splenocytes were harvested from CBA/J mice and
cultured in the presence of mitogen and either medium, commercially
available PGE2, or affinity-purified fungal
PGEx. The results shown are the means (± standard errors)
from two or three experiments. *, P < 0.05 compared
to buffer alone.
|
|

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 5.
Effect of fungal PGE2 on chemokine
production by a human bronchial epithelial cell line. Ca, C. albicans; Cn, C. neoformans. Human epithelial cell line A549 was
cultured in the presence of either medium, PGE2, or
affinity-purified fungal PGEx for 24 h. For IL-6
induction, TNF- (10 ng/ml) was added to the cultures. The IL-8 and
IL-6 concentrations were measured by ELISA. The results shown are the
means (± standard errors) from two or three experiments. *,
P < 0.05 compared to buffer alone.
|
|

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 6.
Effect of fungal PGE2 on mitogen-induced
cytokine production in murine splenocytes. Ca, C. albicans; Cn,
C. neoformans. Splenocytes were harvested from CBA/J mice and
cultured in the presence of ConA and either medium, PGE2,
or affinity-purified fungal PGEx. The supernatants were
harvested after 24 h, and the cytokines were measured by ELISA.
The results shown are the means from two or three experiments. *,
P < 0.05 compared to buffer alone.
|
|
 |
DISCUSSION |
These studies have identified a group of extracellular signal
molecules in fungi which are biologically active on both fungi and
mammalian cells and can modulate host defenses. We have concentrated on
the activity of one of these bioactive lipids, PGEx. It is tempting to assume that the identity of our purified fungal
PGEx is truly PGE2 because the PGE2
monoclonal antibody used to detect (by ELISA) and affinity purify
fungal PGEx binds PGE2 with the highest
affinity. However, the antibody does cross-react with prostaglandins of
the E class (PGE1 [19%], PGE2 [100%], and
PGE3 [43%]). The PGE2 monoclonal antibody
does not recognize isomers of PGE2 or members of the PGA,
PGB, PGD, PGF, or TXB class. Eicosanoids are biologically active lipids
derived from dihomo-
-linolenic acid, arachidonic acid, and
eicosanopentaenoic acid (C20 polyunsaturated fatty acids
[PUFA] which differ only in the number of cis double bonds). Prostanoids are a subfamily of eicosanoids, characterized by an
enzymatically generated ring structure, which includes the prostaglandins and thromboxanes. The different classes of prostanoids are denoted by a letter representing the oxygen substitution on the
ring structure and by a number representing the number of cis double bonds in the lipid. In mammals and other higher
eukaryotes, the initial step of eicosanoid biosynthesis is catalyzed by
cyclooxygenase. We have demonstrated that prostaglandin production by
pathogenic yeasts also involves a cyclooxygenaselike pathway and that
the yeasts can metabolize exogenous arachidonic acid to form
eicosanoids that coelute in HPLC analysis with known prostanoids.
Future studies (including mass spectrometry) will determine whether
PGEx is PGE1, PGE2,
PGE3, or a mixture of E series prostaglandins.
Fungal prostaglandin production occurred de novo, but greater
quantities were produced via metabolism of exogenous arachidonic acid
or other fatty acids (found in SDB). Arachidonic acid-derived eicosanoid production has been reported in nonpathogenic yeasts (3, 9, 12, 13). The nature of the eicosanoids produced by
these fungi varies from species to species, and most require exogenous
substrates. Arachidonic acid is common and abundant in protistan fungi
and certain true fungi, such as the oomycetes and zygomycetes. However,
the occurrence of arachidonic acid in other true fungi, including
pathogenic yeasts, is sporadic (7). Arachidonic acid was
detected among the very long chain fatty acids (C19-25) of
the yeast Rhodotorula (19). The occurrence of
arachidonic acid in C. neoformans and C. albicans
has not been verified (6, 15). It is possible that the
growth conditions and/or methods of fatty acid extraction and
identification were not optimized for detecting very long chain fatty
acids. Our studies and a recently published report have demonstrated
that C. albicans can take up and metabolize exogenous
arachidonic acid (5). Thus, both C. neoformans
and C. albicans can utilize exogenous sources of arachidonic
acid for eicosanoid synthesis. This opens up the possibility that
host-derived arachidonic acid may be used by fungi for prostaglandin
synthesis. It is also possible that the fungal prostaglandins are not
derived from arachidonic acid but are produced from shorter-chain PUFA.
We have also identified that phospholipase B mutants of C. neoformans have defects in prostaglandin synthesis (M. C. Noverr, unpublished observation), suggesting that phospholipase may
participate in PUFA release. The identity of the C20 PUFA
determines the type of prostanoid produced (i.e., dihomo-
-linolenic
acid, arachidonic acid, and eicosanopentaenoic acid serve as the
substrates for PG1, PG2, and PG3
series prostanoids, respectively). Future studies will focus on
identifying the endogenous substrates for prostaglandin synthesis.
Overall, our data demonstrate that fungal eicosanoids can be
synthesized from exogenous (host?) or endogenous (fungal) substrates.
We have demonstrated that cyclooxygenase plays a critical role in
fungal metabolism. In mammals and other higher eukaryotes, the initial
step of eicosanoid biosynthesis is catalyzed by cyclooxygenase. Although a fungal cyclooxygenase has not been identified, the cyclooxygenase inhibitors indomethacin, etodolac, and piroxicam all
block PGEx production by C. neoformans and
C. albicans. We cannot rule out the possibility that
decreases in prostaglandin production caused by these inhibitors are
due to decreases in viability (as opposed to inhibition of
cyclooxygenase activity). In preliminary studies, we have identified a
cyclooxygenase-cross-reactive protein in C. neoformans cell
lysates by Western blotting with an anti-rat cyclooxygenase antibody
(data not shown). Cyclooxygenase inhibitors have also been shown to
arrest the growth or prevent the sexual maturation of some species of
environmental fungi (2, 10). The data shown in Fig. 2
suggest not only that a cyclooxygenase-dependent metabolic pathway is
found in C. albicans and C. neoformans but that
blocking this pathway kills the yeast. Thus, these signal molecules
(prostaglandins and other eicosanoids) appear to be generated via a
conserved biochemical pathway that is important in both fungal
metabolism and host defense.
The most striking aspect of these studies is that fungal
PGEx exhibits the same activities reported for mammalian
PGE2 in the five assays tested in this report. Fungal
PGEx was active on mammalian cells and could down-modulate
chemokine production and TNF-
production and proliferation while
up-regulating IL-10 production. Furthermore, fungal PGEx
could also promote Candida germ tube formation. These are
all activities previously documented for mammalian PGE2
(8, 11, 23, 26, 27). This observation offers a potential
mechanism to explain the recent reports that chemokine production by
endothelial cells is inhibited by live, but not killed, cryptococci
(17). In addition, the observation that C. albicans produced and responded to PGEx (Fig. 2 and 3) provides a microbiological explanation for the ability of human PGE2 to enhance C. albicans germ tube formation
(8). The germinated hyphal form of C. albicans
is better able to adhere to and penetrate host tissues than the yeast
form (22, 25). Thus, it is likely that fungal
PGEx is important in C. albicans pathogenesis,
and host PGE2 could actually exacerbate the infection.
Given the biological activity of the purified fungal eicosanoids, they
have the potential to mediate host-pathogen "cross talk," in which
the pathogen can down-regulate (local) host immune responses at the
site of infection and the host can inadvertently augment pathogen
virulence. The result of such interactions could be an immunological
stalemate, i.e., chronic low-grade infection or parasitism. The most
common feature of fungal infections is their chronic persistence within
tissues of otherwise healthy individuals, ranging in severity from
athlete's foot to chronic vaginitis to pulmonary granulomas
(14). Prostaglandins can also modulate the Th1-Th2 balance
of a response and promote tissue eosinophilia, a feature of some
chronic fungal infections (1, 16, 20, 24). While we do not
have isogenic strains of prostaglandin knockout yeast, we have
identified a laboratory strain of C. neoformans (2E-TuC)
that produces less prostaglandin than other clinical isolates (e. g.,
24067E, 145, and H99). Interestingly, this low-prostaglandin strain
does not induce the pulmonary eosinophilia in genetically susceptible
(but immunologically normal) C57BL/6 mice seen with other C. neoformans strains (data not shown). In conclusion, the discovery
that pathogenic fungi produce and respond to immunomodulatory eicosanoids reveals a virulence mechanism that has potentially great
implications for understanding the mechanisms of chronic fungal
infection, immune deviation, and fungi as disease cofactors.
 |
ACKNOWLEDGMENTS |
We wish to thank Dierdra Williams for her work on the chemokine assays.
This work was supported by a New Investigator Award in Molecular
Pathogenic Mycology from the Burroughs-Wellcome Fund (G.B.H.). M.C.N.
is supported by NIH-NIAID training grant T32AI07528.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109-0642. Phone:
(734) 936-9368. Fax: (734) 764-4556. E-mail: ghuff{at}umich.edu.
Editor:
T. R. Kozel
 |
REFERENCES |
| 1.
|
Betz, M., and B. S. Fox.
1991.
Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines.
J. Immunol.
146:108-113[Abstract].
|
| 2.
|
Botha, A.,
J. Kock,
D. Coetzee,
N. Linde, and M. van Dyk.
1992.
Yeast eicosanoids. II. The influence of non-steroidal anti-inflammatory drugs on the life cycle of Dipodascopsis.
Syst. Appl. Microbiol.
15:155-160.
|
| 3.
|
Botha, A.,
J. Kock, and S. Nigam.
1998.
The production of eicosanoid precusors by mucoralean fungi.
In
H. Sinzinger, B. Samuelsson, J. Vane, R. Paoletti, P. Ramwell, and P. Wong (ed.), Recent advances in prostaglandin, thromboxane, and leukotriene Research. Plenum Press, New York, N.Y.
|
| 4.
|
Demeure, C. E.,
L.-P. Yang,
C. Desjardins,
P. Raynauld, and G. Delespesse.
1997.
Prostaglandin E2 primes naive T cells for the production of anti-inflammatory cytokines.
Eur. J. Immunol.
27:3526-3531[Medline].
|
| 5.
|
Deva, R.,
R. Ciccoli,
T. Schewe,
J. L. Kock, and S. Nigam.
2000.
Arachidonic acid stimulates cell growth and forms a novel oxygenated metabolite in Candida albicans.
Biochim. Biophys. Acta
1486:299-311[Medline].
|
| 6.
|
Gangopadhyay, P.,
H. Thadepalli,
I. Roy, and A. Ansari.
1979.
Identification of species of Candida, Cryptococcus, and Torulopsis by gas-liquid chromatography.
J. Infect. Dis.
140:952-958[Medline].
|
| 7.
|
Herman, R. P.
1998.
Oxylipin production and action in fungi and related organisms.
In
A. F. Rowley, H. Kuhn, and T. Schewe (ed.), Eicosanoids and related compounds in plants and animals. Princeton University Press, Princeton, N.J.
|
| 8.
|
Kalo-Klein, A., and S. Witkin.
1990.
Prostaglandin E2 enhances and gamma interferon inhibits germ tube formation in Candida albicans.
Infect. Immun.
58:260-262[Abstract/Free Full Text].
|
| 9.
|
Kock, J.,
D. Coetzee,
M. van Dyk,
M. Truscott,
P. Cloete,
V. van Wyk, and O. Augustyn.
1991.
Evidence for pharmacologically active prostaglandins in yeasts.
S. Afr. J. Sci.
87:73-76.
|
| 10.
|
Krystofova, S.,
L. Vareka,
V. Vollek,
J. Grimova, and V. Bettina.
1994.
Growth and conidiation of Tricoderma viride are affected by non-steroidal antiinflammatory agents.
Folia Microbiol.
39:44-48.
|
| 11.
|
Kunkel, S. L.,
M. Spengler,
M. A. May,
R. Spengler,
J. Larrick, and D. Remick.
1988.
Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression.
J. Biol. Chem.
263:5380-5384[Abstract/Free Full Text].
|
| 12.
|
Lamacka, M., and J. Sajbidor.
1995.
The occurence of prostaglandins and related compounds in lower organisms.
Prostaglandins Leukot. Essent. Fatty Acids
52:357-364[CrossRef][Medline].
|
| 13.
|
Lodewyk, J.,
J. Kock,
P. Venter,
A. Botha,
D. Coetzee,
P. Botes, and S. Nigam.
1997.
The production of biologically active eicosanoids by yeasts.
Adv. Exp. Med. Biol.
433:217-219[Medline].
|
| 14.
|
Mandell, G. L.,
J. E. Bennett, and R. Dolin (ed.).
1995.
Mandell, Douglas, and Bennett's principles and practice of infectious diseases.
Churchill Livingstone, New York, N.Y.
|
| 15.
|
Marumo, K., and Y. Aoki.
1990.
Disciminant analysis of cellular fatty acids of Candida species, Torulopsis glabrata, and Cryptococcus neoformans determined by gas-liquid chromatography.
J. Clin. Microbiol.
28:1509-1513[Abstract/Free Full Text].
|
| 16.
|
Matsuoka, T.,
M. Hirata,
H. Tanaka,
Y. Takahashi,
T. Murata,
K. Kabashima,
Y. Sugimoto,
T. Kobayashi,
F. Ushikubi,
Y. Aze,
N. Eguchi,
Y. Urade,
N. Yoshida,
K. Kimura,
A. Mizoguchi,
Y. Honda,
H. Nagai, and S. Narumiya.
2000.
Prostaglandin D2 as a mediator of allergic asthma.
Science
287:2013-2019[Abstract/Free Full Text].
|
| 17.
|
Mozaffarian, N.,
A. Casadevall, and J. W. Berman.
2000.
Inhibition of human endothelial cell chemokine production by the opportunistic fungal pathogen Cryptococcus neoformans.
J. Immunol.
165:1541-1547[Abstract/Free Full Text].
|
| 18.
|
Murphy, J. W.,
A. Zhou, and S. C. Wong.
1997.
Direct interactions of human natural killer cells with Cryptococcus neoformans inhibit granulocyte-macrophage colony-stimulating factor and tumor necrosis factor alpha production.
Infect. Immun.
65:4565-4571.
|
| 19.
|
Perrier, V.,
E. Dubreucq, and P. Galzy.
1995.
Fatty acid and carotenoid composition of Rhodotorula strains.
Arch. Microbiol.
164:173-179[Medline].
|
| 20.
|
Peters-Golden, M.
1997.
Lipid mediator synthesis by lung macrophages, p. 151-182.
In
M. F. Lipscomb, and S. W. Russell (ed.), Lung macrophages and dendritic cells in health and disease, vol. 102. Marcel Dekker, Inc, New York, N.Y.
|
| 21.
|
Romani, L., and S. H. Kaufmann.
1998.
Immunity to fungi: editorial overview.
Res. Immunol.
149:277-281[CrossRef][Medline].
|
| 22.
|
Sandin, R. L.,
R. J. Rogers,
R. J. Patterson, and E. S. Beneke.
1982.
Evidence for mannose-mediated adherence of Candida albicans to human buccal cells in vitro.
Infect. Immun.
35:79-85[Abstract/Free Full Text].
|
| 23.
|
Sergeeva, M. G.,
M. V. Gonchar,
A. T. Mevkh, and S. D. Varfolomeyev.
1997.
Prostaglandin E2 biphasic control of lymphocyte proliferation inhibition by picomolar concentrations.
FEBS Lett.
418:235-238[CrossRef][Medline].
|
| 24.
|
Snijdewint, F. G.,
P. Kalinski,
E. A. Wierenga,
J. D. Bos, and M. L. Kapsenberg.
1993.
Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes.
J. Immunol.
150:5321-5329[Abstract].
|
| 25.
|
Sobel, J. D.,
G. Muller, and H. R. Buckley.
1984.
Critical role of germ tube formation in the pathogenesis of candidal vaginitis.
Infect. Immun.
44:576-580[Abstract/Free Full Text].
|
| 26.
|
Standiford, T. J.,
S. L. Kunkel,
M. W. Rolfe,
H. L. Evanoff,
R. M. Allen, and R. M. Strieter.
1992.
Regulation of human alveolar macrophage- and blood monocyte-derived interleukin-8 by prostaglandin E2 and dexamethasone.
Am. J. Respir. Cell Mol. Biol.
6:75-81.
|
| 27.
|
Strassmann, G.,
V. Patil-Koota,
F. Finkelman,
M. Fong, and T. Kambayashi.
1994.
Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2.
J. Exp. Med.
180:2365-2370[Abstract/Free Full Text].
|
| 28.
|
Witkin, S. S.,
J. Jeremias, and W. J. Ledger.
1988.
A localized vaginal allergic response in women with recurrent vaginitis.
J. Allergy Clin. Immunol.
81:412-416[CrossRef][Medline].
|
Infection and Immunity, May 2001, p. 2957-2963, Vol. 69, No. 5
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.5.2957-2963.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Yuhki, K.-i., Ushikubi, F., Naraba, H., Ueno, A., Kato, H., Kojima, F., Narumiya, S., Sugimoto, Y., Matsushita, M., Oh-ishi, S.
(2008). Prostaglandin I2 Plays a Key Role in Zymosan-Induced Mouse Pleurisy. J. Pharmacol. Exp. Ther.
325: 601-609
[Abstract]
[Full Text]
-
Rhome, R., McQuiston, T., Kechichian, T., Bielawska, A., Hennig, M., Drago, M., Morace, G., Luberto, C., Del Poeta, M.
(2007). Biosynthesis and Immunogenicity of Glucosylceramide in Cryptococcus neoformans and Other Human Pathogens. Eukaryot Cell
6: 1715-1726
[Full Text]
-
Erb-Downward, J. R., Noverr, M. C.
(2007). Characterization of Prostaglandin E2 Production by Candida albicans. Infect. Immun.
75: 3498-3505
[Abstract]
[Full Text]
-
Erb-Downward, J. R., Huffnagle, G. B.
(2007). Cryptococcus neoformans Produces Authentic Prostaglandin E2 without a Cyclooxygenase. Eukaryot Cell
6: 346-350
[Abstract]
[Full Text]
-
Wright, L. C., Santangelo, R. M., Ganendren, R., Payne, J., Djordjevic, J. T., Sorrell, T. C.
(2007). Cryptococcal Lipid Metabolism: Phospholipase B1 Is Implicated in Transcellular Metabolism of Macrophage-Derived Lipids. Eukaryot Cell
6: 37-47
[Abstract]
[Full Text]
-
Lindell, D. M., Ballinger, M. N., McDonald, R. A., Toews, G. B., Huffnagle, G. B.
(2006). Immunologic Homeostasis during Infection: Coexistence of Strong Pulmonary Cell-Mediated Immunity to Secondary Cryptococcus neoformans Infection While the Primary Infection Still Persists at Low Levels in the Lungs. J. Immunol.
177: 4652-4661
[Abstract]
[Full Text]
-
Alem, M. A. S., Oteef, M. D. Y., Flowers, T. H., Douglas, L. J.
(2006). Production of Tyrosol by Candida albicans Biofilms and Its Role in Quorum Sensing and Biofilm Development. Eukaryot Cell
5: 1770-1779
[Abstract]
[Full Text]
-
Alem, M. A., Douglas, L J.
(2005). Prostaglandin production during growth of Candida albicans biofilms. J Med Microbiol
54: 1001-1005
[Abstract]
[Full Text]
-
Tsitsigiannis, D. I., Bok, J.-W., Andes, D., Nielsen, K. F., Frisvad, J. C., Keller, N. P.
(2005). Aspergillus Cyclooxygenase-Like Enzymes Are Associated with Prostaglandin Production and Virulence. Infect. Immun.
73: 4548-4559
[Abstract]
[Full Text]
-
Noverr, M. C., Falkowski, N. R., McDonald, R. A., McKenzie, A. N., Huffnagle, G. B.
(2005). Development of Allergic Airway Disease in Mice following Antibiotic Therapy and Fungal Microbiota Increase: Role of Host Genetics, Antigen, and Interleukin-13. Infect. Immun.
73: 30-38
[Abstract]
[Full Text]
-
Herring, A. C., Falkowski, N. R., Chen, G.-H., McDonald, R. A., Toews, G. B., Huffnagle, G. B.
(2005). Transient Neutralization of Tumor Necrosis Factor Alpha Can Produce a Chronic Fungal Infection in an Immunocompetent Host: Potential Role of Immature Dendritic Cells. Infect. Immun.
73: 39-49
[Abstract]
[Full Text]
-
Noverr, M. C., Huffnagle, G. B.
(2004). Regulation of Candida albicans Morphogenesis by Fatty Acid Metabolites. Infect. Immun.
72: 6206-6210
[Abstract]
[Full Text]
-
Noverr, M. C., Noggle, R. M., Toews, G. B., Huffnagle, G. B.
(2004). Role of Antibiotics and Fungal Microbiota in Driving Pulmonary Allergic Responses. Infect. Immun.
72: 4996-5003
[Abstract]
[Full Text]
-
Alem, M. A. S., Douglas, L. J.
(2004). Effects of Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs on Biofilms and Planktonic Cells of Candida albicans. Antimicrob. Agents Chemother.
48: 41-47
[Abstract]
[Full Text]
-
Mullick, A., Elias, M., Harakidas, P., Marcil, A., Whiteway, M., Ge, B., Hudson, T. J., Caron, A. W., Bourget, L., Picard, S., Jovcevski, O., Massie, B., Thomas, D. Y.
(2004). Gene Expression in HL60 Granulocytoids and Human Polymorphonuclear Leukocytes Exposed to Candida albicans{dagger}. Infect. Immun.
72: 414-429
[Abstract]
[Full Text]
-
Giles, S., Czuprynski, C.
(2003). Novel Role for Albumin in Innate Immunity: Serum Albumin Inhibits the Growth of Blastomyces dermatitidis Yeast Form In Vitro. Infect. Immun.
71: 6648-6652
[Abstract]
[Full Text]
-
Deva, R., Shankaranarayanan, P., Ciccoli, R., Nigam, S.
(2003). Candida albicans Induces Selectively Transcriptional Activation of Cyclooxygenase-2 in HeLa Cells: Pivotal Roles of Toll-Like Receptors, p38 Mitogen-Activated Protein Kinase, and NF-{kappa}B. J. Immunol.
171: 3047-3055
[Abstract]
[Full Text]
-
Noverr, M. C., Erb-Downward, J. R., Huffnagle, G. B.
(2003). Production of Eicosanoids and Other Oxylipins by Pathogenic Eukaryotic Microbes. Clin. Microbiol. Rev.
16: 517-533
[Abstract]
[Full Text]
-
Noverr, M. C., Cox, G. M., Perfect, J. R., Huffnagle, G. B.
(2003). Role of PLB1 in Pulmonary Inflammation and Cryptococcal Eicosanoid Production. Infect. Immun.
71: 1538-1547
[Abstract]
[Full Text]
-
Ellerbroek, P. M., Hoepelman, A. I. M., Wolbers, F., Zwaginga, J. J., Coenjaerts, F. E. J.
(2002). Cryptococcal Glucuronoxylomannan Inhibits Adhesion of Neutrophils to Stimulated Endothelium In Vitro by Affecting Both Neutrophils and Endothelial Cells. Infect. Immun.
70: 4762-4771
[Abstract]
[Full Text]
-
Herring, A. C., Lee, J., McDonald, R. A., Toews, G. B., Huffnagle, G. B.
(2002). Induction of Interleukin-12 and Gamma Interferon Requires Tumor Necrosis Factor Alpha for Protective T1-Cell-Mediated Immunity to Pulmonary Cryptococcus neoformans Infection. Infect. Immun.
70: 2959-2964
[Abstract]
[Full Text]
-
Noverr, M. C., Toews, G. B., Huffnagle, G. B.
(2002). Production of Prostaglandins and Leukotrienes by Pathogenic Fungi. Infect. Immun.
70: 400-402
[Abstract]
[Full Text]